Allarity Therapeutics CEO Letter to Shareholders: Read the letter from CEO James G. Cullem to Allarity’s shareholders and other stakeholders, published on August 11, 2023
Our Lead Program: Stenoparib
Stenoparib is at the forefront of Allarity’s mission to personalize cancer care. Here’s why it’s our lead program:
Versatility: While our current Phase 2 study is focused on advancing stenoparib toward eventual approval in ovarian cancer, we believe the drug’s potential may extend to multiple cancer types, making it a versatile weapon against cancer.

Molecular model of Allarity’s lead asset: stenoparib
Our Pipeline
Allarity’s focused pipeline is centered on stenoparib, an orally available small molecule. Its unique dual-action mechanism inhibits both PARP1/2 and telomerase maintenance enzymes.
Our Platform
Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug.
Publications
Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.
News
Events
TBA
The DRP® Platform
No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors"We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class companion diagnostics platform."
James G. Cullem, CEO
